Singapore trial aims to boost survival in advanced nasal cancer
NCT ID NCT05305131
Summary
This study is testing if adding two newer drugs (pembrolizumab and bevacizumab) to standard chemotherapy before radiation is better for patients with advanced nasopharyngeal cancer. It will involve 50 adults with newly diagnosed, locally advanced cancer who have not yet started treatment. The goal is to see if the four-drug combination leads to better tumor response and longer survival without the cancer returning.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National University Hospital
RECRUITINGSingapore, Singapore
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.